Beacon Therapeutics reports successful gene-therapy trial for rare X-linked retinitis pigmentosa

Beacon Therapeutics announced that its gene-therapy candidate for X-linked retinitis pigmentosa (XLRP) achieved its primary endpoint in a pivotal trial.

The result marks a breakthrough for the rare inherited eye disorder, a condition that has eluded effective treatments despite efforts by larger companies such as Johnson & Johnson and Biogen.

The company said the data support continued development and could pave the way for regulatory submissions, although details on the trial phase and patient numbers were not disclosed.